

FOI 24/014 - FOI request

MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

Wed 31/01/2024 17:19

To [REDACTED]

Our ref: FOI 24/014

Dear [REDACTED]

Thank you for your request of 03 January 2023 under the Freedom of Information Act. You requested:

- Any correspondence between the UK government and Takeda Pharmaceuticals in 2022, 2023 and 2024 regarding ADHD medicine shortages

When we receive a request such as this, which would cover correspondence that could be sent or received from anywhere in the MHRA, we conduct a search across all MHRA mailboxes and documents. To allow us to do that we need to identify specific search terms so that we can build a search to retrieve relevant results.

In order to take your request forward we need to seek clarification from you. The term 'ADHD medicine' is not a category in itself, nor is it a specific enough search term for us to use. Our interpretation of your request is that you are referring to medicines which have, in their indication, the treatment of ADHD disorders. However, can you confirm whether our interpretation is correct? If so, we would be grateful if you could please provide details of, or list, the specific medicines you would like information about. If our interpretation is incorrect then please provide further detail to enable us to assist.

Once we receive your response we will log this as a new request and take forward.

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Experience Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU

From: [REDACTED] >
Sent: Wednesday, January 3, 2024 6:06 PM
To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Subject: FOI 24/014 - FOI request

You don't often get email from [REDACTED]

Hello,

I am requesting the following information under the Freedom of Information Act:

- Any correspondence between the UK government and Takeda Pharmaceuticals in 2022, 2023 and 2024 regarding ADHD medicine shortages

Best wishes,
Amy

--

[REDACTED]

[REDACTED]

*This email was sent by [REDACTED] registered office [REDACTED]
[REDACTED] Registered in England and Wales with company number [REDACTED]
[REDACTED] This e-mail may contain confidential information. If you are not the intended recipient, please notify the sender immediately, delete all copies and do not distribute it further. It could also contain personal views which are not necessarily those of [REDACTED] We may monitor outgoing or incoming emails as permitted by law.*

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)